Glenmark Expands US Portfolio with Acetylcysteine Injection Launch
Glenmark Pharmaceuticals Ltd announced that its US subsidiary, Glenmark Pharmaceuticals Inc., has acquired the Abbreviated New Drug Application (ANDA) for Acetylcysteine Injection from Aspen Pharma USA Inc. The transaction terms have not been disclosed.
The injection, containing a potency of 6 gm/30 mL (200 mg/mL) in single-dose vials, is mainly applied to treat acetaminophen overdose. Glenmark reported that its product should produce the same therapeutic response as Acetadote Injection, the reference-listed drug of Cumberland Pharmaceuticals Inc.
This is a fantastic addition to our injectable franchise in the US market as we continue to fuel growth for the hospital segment," said Marc Kikuchi, President & Business Head, North America, Glenmark Pharmaceuticals.
The deal enhances Glenmark's US hospital market presence, adding to its portfolio of acute care and emergency-use drugs. With the introduction of a cost-effective and dependable replacement for Acetadote, the firm hopes to cater to increasing needs for critical treatment in acute care environments.
Glenmark reaffirms its focus on increasing its product line and delivering affordable healthcare options with this launch, further cementing its place in the US pharmaceutical industry.
